HRGN
HARVARD APPRATS REG TCH
stockOTC
biostage, inc. (otcqb: bstg) is a pioneering biotechnology company developing bioengineered organ implants to address unmet needs in the treatment of life-threatening cancer, traumas and congenital abnormalities of the esophagus, bronchus and trachea. the company's cellframe™ technology platform is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. combining a synthetic scaffold with tissue engineering and cell biology, biostage's cellframe™ platform is used to create organ specific cellspan™ implants. the cellspan™ implant is delivered directly to the site where tissue regeneration is needed, and has been designed to promote in situ tissue regeneration by providing both stem cell-derived biological signals, and three-dimensional guidance and support for cell growth differentiation. recent large animal data delivered promising results as cellframe™-based cellspan™ implants applied to the esophagus achieved regener
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.15 | 2026-09-28 | +1.86% | -4.954 |
| 1M | 2.35 | 2026-09-03 | -6.81% | 6.333 |
| 3M | 1.05 | 2026-07-06 | +108.57% | 5.633 |
| 6M | 1.57 | 2026-04-08 | +39.31% | 1.076 |
| 1Y | 1.91 | 2025-10-06 | +14.66% | 0.333 |
| 2Y | 3.97 | 2024-10-04 | -44.84% | — |
| 5Y | 4.45 | 2023-07-20 | -50.79% | 0.098 |
HARVARD APPRATS REG TCH (OTC:HRGN) stock price today is $2.19, and today's volume is 1,215. HRGN is down 0.455% today. The 30 day average volume is 2,532. HRGN market cap is $31.46M with 14.37M shares outstanding.